+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Japan Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 118 Pages
  • September 2023
  • Region: Japan
  • Grand View Research
  • ID: 5681772
Description Jump to:
The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, registering a CAGR of 5.9% from 2023 to 2030. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

Japan Contract Development And Manufacturing Organization Market Report Highlights

  • The API product segment accounted for the largest revenue share of 81.0% in 2022. The product segment is divided into API and drug product
  • Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
  • The oncology segment is anticipated to register the fastest CAGR of 6.4% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
  • In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Workflow
1.1.3. Application
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Workflow
2.2.3. Application
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Japan Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Japan Contract Development and Manufacturing Organization Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Japan Contract Development and Manufacturing Organization: Product Estimates & Trend Analysis
4.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
4.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
4.3. API
4.3.1. API market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Type
4.3.2.1. Type market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.2. Traditional active pharmaceutical ingredient (traditional API)
4.3.2.2.1. Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.3. Highly potent active pharmaceutical ingredient (HP-API)
4.3.2.3.1. Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.4. Antibody drug conjugate (ADC)
4.3.2.4.1. Antibody drug conjugate (ADC) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.5. Others
4.3.2.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Synthesis
4.3.3.1. Synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.2. Synthetic
4.3.3.2.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.3. Solid
4.3.3.3.1. Solid market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.4. Liquid
4.3.3.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.5. Biotech
4.3.3.5.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Drug
4.3.4.1. Drug market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4.2. Innovative
4.3.4.2.1. Innovative market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4.3. Generic
4.3.4.3.1. Generic market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5. Manufacturing
4.3.5.1. Manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5.2. Continuous manufacturing
4.3.5.2.1. Continuous manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5.3. Batch manufacturing
4.3.5.3.1. Batch manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Drug Product
4.4.1. Drug product market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Oral solid dose
4.4.2.1. Oral solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Semi-solid dose
4.4.3.1. Semi-solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Liquid dose
4.4.4.1. Liquid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Others
4.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Japan Contract Development and Manufacturing Organization: Workflow Estimates & Trend Analysis
5.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
5.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Clinical
5.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Commercial
5.4.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Japan Contract Development and Manufacturing Organization: Application Estimates & Trend Analysis
6.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
6.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Oncology
6.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Hormonal
6.4.1. Hormonal market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Glaucoma
6.5.1. Glaucoma market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Cardiovascular Disease
6.6.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes delivery market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. CORDENPHARMA INTERNATIONAL
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. WuXi AppTec
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Cambrex Corporation
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Recipharm AB
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Lonza
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Catalent, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Laboratory Corporation of America Holdings
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Thermo Fisher Scientific, Inc
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Samsung BioLogics
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. SUMITOMO CHEMICAL COMPANY, LIMITED
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. CMIC HOLDINGS Co., LTD
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Bushu Pharmaceuticals LTD.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. NIPRO
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 Japan contract development and manufacturing organization market, by product, 2018 - 2030 (USD Million)
Table 3 Japan contract development and manufacturing organization market, by workflow, 2018 - 2030 (USD Million)
Table 4 Japa contract development and manufacturing organization market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Japan contract development and manufacturing organization: Market outlook
Fig. 9 Japan contract development and manufacturing organization: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Japan contract development and manufacturing organization market driver impact
Fig. 15 Japan contract development and manufacturing organization market restraint impact
Fig. 16 Japan contract development and manufacturing organization market strategic initiatives analysis
Fig. 17 Japan contract development and manufacturing organization market: Product movement analysis
Fig. 18 Japan contract development and manufacturing organization market: Product outlook and key takeaways
Fig. 19 API market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Type market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Antibody drug conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Solid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Liquid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Drug market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Innovative market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Generic market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Drug product market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan contract development and manufacturing organization market: Workflow movement analysis
Fig. 42 Japan contract development and manufacturing organization market: Workflow outlook and key takeaways
Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Japan contract development and manufacturing organization market: Application movement analysis
Fig. 46 Japan contract development and manufacturing organization market: Application outlook and key takeaways
Fig. 47 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • CORDENPHARMA INTERNATIONAL
  • WuXi AppTec
  • Cambrex Corporation
  • Recipharm AB
  • Lonza
  • Catalent, Inc.
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific, Inc
  • Samsung BioLogics
  • FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
  • SUMITOMO CHEMICAL COMPANY, LIMITED
  • CMIC HOLDINGS Co., LTD
  • Bushu Pharmaceuticals LTD.
  • NIPRO

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages118
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 11.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.5 Billion
Compound Annual Growth Rate5.9%
Regions CoveredJapan
No. of Companies Mentioned14

Related Topics

Related Reports

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023-2030 - Product Image

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023-2030

  • Report
  • 175 Pages
  • Global
From
Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 175 Pages
  • Global
From
Global Healthcare Contract Development & Manufacturing Organization Market by Services, End-User - Forecast 2024-2030 - Product Image

Global Healthcare Contract Development & Manufacturing Organization Market by Services, End-User - Forecast 2024-2030

  • Report
  • 196 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 380 Pages
  • Global
From
Small Molecules Contract Development and Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Small Molecules Contract Development and Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.